Clinical trial NCT05459181: HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)
Official title: Molecular Outcome Surveillance Using AlloSure and AlloMap Guided Immunomodulation in Cardiac Transplant
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Heart Transplant
Immunosuppression
Allograft
Keywords: HeartCare
Allograft loss and survival
Calcineurin inhibitors
Chronic immunosuppression
Steroid avoidance
Donor-specific antibodies
Donor-derived cell-free DNA
AlloSure
AlloMap
Gene expression profiling
Lead sponsor: CareDx
Sponsor class: INDUSTRY
First posted: 2022-07-14
Enrollment: 930
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is an unblinded, randomized, controlled, two-arm interventional research study enrolling patients who are undergoing heart transplantation. The aim of the study is to determine whether patients at low risk of rejection can safely reduce the doses of their post-transplant immunosuppression medications using a combination of tests that include donor-specific antibodies (DSA), histology (looking at tissue from the donor heart), donor-derived cell-free DNA (AlloSure), and gene expression profiling (AlloMap). Eligible participants will be randomized in a 1:1 ratio into the HeartCare immune-optimization (intervention) arm or the corresponding observational (control) arm. AlloSure and AlloMap are the components of the HeartCare panel developed by CareDx.

Detailed description: This is an open-label randomized controlled two-arm interventional trial. Eligible patients starting triple maintenance therapy (tacrolimus, mycophenolate mofetil and prednisone) post-transplant will be randomized at a 1:1 ratio into the HeartCare immuno-optimization (intervention) arm or the corresponding observational (control) arm. Participants enrolled in the study will begin HeartCare testing as specified in the protocol. All centers will use their own induction regimen provided that the induction practice represents standard of care. Participants will be randomized at 4-weeks post-transplant, assuming they meet requisite clinical/laboratory/histological criteria to proceed. In the Interventional Arm, participants will begin stepwise optimization of their immunosuppression regimen based on their HeartCare, clinical DSA testing, and histology. Patient data (including diagnosis and biopsy outcomes) will be collected through an electronic data capture portal where key results will be transcribed from the hospital EMR into the portal.

Eligibility criteria: Inclusion Criteria:

1. Heart transplant recipients \<2 weeks post-transplant
2. Patients aged 18 years or older
3. Planned post-transplant maintenance immunosuppression regimen consisting of prednisolone, tacrolimus and mycophenolate
4. Female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception during the trial and for 3 months thereafter
5. Participant is willing and able to give informed consent for participation in the trial
6. In the Investigator's opinion, is able and willing to comply with all trial requirements

Exclusion Criteria:

The participant may not enter the trial if ANY of the following apply:

1. Multi-visceral transplant recipients
2. Female participant who is pregnant, lactating or planning pregnancy during the trial
3. Heart transplant recipients undergoing desensitization protocols prior to transplant based off high immunological risk profiles (determined by treating clinician)
4. Chronic oral steroid use for any reason that cannot be tapered off and discontinued
5. Planned post-transplant immunosuppression regimen utilizing cyclosporine, azathioprine, mTOR inhibitors, and/or co-stimulatory blockers
6. Contraindication to having AlloSure or AlloMap testing
7. Participant with life expectancy of less than 6 months or is inappropriate for immuno-optimization (including those patients at increased risk of primary disease recurrence w/ reduction in post-transplant immunosuppression)
8. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial. This includes clinical events that would significantly impact post-transplant immunosuppression such as major infectious complications or significant rejection episodes within the first month post-transplant.
9. Participants who are currently or have previously participated in another research trial involving an investigational immunological drug in the past 12 weeks
10. Any condition that would preclude protocol biopsies

Randomization Criteria (assessed at Week 4)

The participant may not proceed with randomization if ANY of the following apply at Week 4 post-transplant:

1. Maintenance immunosuppression that includes cyclosporine, azathioprine, mTOR inhibitors, and/or co-stimulatory blockers
2. Any episodes of biopsy-proven acute rejection (ACR ≥2R or AMR\*)
3. Abnormal molecular profile defined as AlloSure \>0.2%
4. Allograft dysfunction defined as LVEF \<45%
5. eGFR \<30mL/min
6. Presence of DSA (persistence of any pre-transplant DSA or dnDSA) \*AMR 1 (H+) with DSA/graft dysfunction or AMR \> 2

Primary outcomes:
measure: Incidence of Allograft loss at 12-months post-transplant (safety)
timeFrame: 12 months
measure: Incidence of Allograft loss at 24-months post-transplant (safety)
timeFrame: 24 months
measure: Total number of acute rejection episodes (ACR >2R or AMR*) at 12-months post-transplant (safety)
timeFrame: 12 months
measure: Total number of acute rejection episodes (ACR >2R or AMR*) at 24-months post-transplant (safety)
timeFrame: 24 months
measure: EQ-5D survey performed at 12-months post-transplant to assess allograft function (safety)
timeFrame: 12 months
measure: TTE imaging performed at 12-months post-transplant to assess allograft function (safety)
timeFrame: 12 months
measure: EQ-5D survey performed at 24-months post-transplant to assess allograft function (safety)
timeFrame: 24 months
measure: TTE imaging performed at 24-months post-transplant to assess allograft function (safety)
timeFrame: 24 months
measure: Incidence of dnDSA formation at 12-months post-transplant (safety and efficacy)
timeFrame: 12 months
measure: Incidence of dnDSA formation at 24-months post-transplant (safety and efficacy)
timeFrame: 24 months
measure: Change in eGFR at 12-months post-transplant (efficacy)
timeFrame: 12 months
measure: Change in eGFR at 24-months post-transplant (efficacy)
timeFrame: 24 months
measure: Total number of biopsies performed post-transplant, including both surveillance and clinically indicated biopsies (efficacy)
timeFrame: 24 months
Secondary outcomes:
measure: Histological assessment of tissue biopsy with paired AlloSure dd-cfDNA and AlloMap GEP results (HeartCare) - performed both 'For Cause' and 'Surveillance' using standard biopsy assessment.
timeFrame: 6 months
measure: Association between AlloSure dd-cfDNA and AlloMap GEP (HeartCare) results with successful immuno-optimization, longitudinal clinical/laboratory parameters (dnDSA), and histologic data (allograft rejection, CAV).
timeFrame: 24 months
measure: Data collection from patient medical record, to capture episodes of infection, viral PCR results, changes in immunosuppression and treatment of rejection, as well as all adverse advents.
timeFrame: 24 months
Other outcomes:
Locations:
Study officials:
References: